Alphamab Oncology (HKG:9966)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.70
+0.61 (4.66%)
Sep 30, 2025, 4:08 PM HKT
4.66%
Market Cap13.31B
Revenue (ttm)861.24M
Net Income (ttm)255.11M
Shares Out971.20M
EPS (ttm)0.26
PE Ratio52.91
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,216,000
Average Volume4,223,377
Open13.19
Previous Close13.09
Day's Range13.10 - 13.72
52-Week Range3.05 - 13.70
Beta0.36
RSI66.47
Earnings DateNov 28, 2025

About Alphamab Oncology

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 420
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9966
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.